- Telo Genomics Corp. (TELO) launches a study for its lead product for smoldering multiple myeloma (SMM) patients and completes research and development projects
- The company’s lead product targets high risk SMM patients that will benefit from immediate treatment intervention
- The development stages and validation are expected to be completed within 12-18 months
- Telo also has conducted several internal research and development projects to maximize accuracy and elevate its efficiency
- The completion of projects increases the efficiency and productivity of Telo by over 40 per cent
- Telo Genomics Corp. (TELO) is unchanged trading at $0.32 per share as of 11:16 a.m. EST
Telo Genomics (TELO) has announced a study for its lead product for smoldering multiple myeloma (SMM) patients and completed research and development projects.
Telo has recently received the SMM patient samples from a validation study that the company is pursuing.
The study will be conducted by Dr. Hans Knecht, Telo’s Clinical Advisor.
The launched study will accelerate Telo’s ongoing collaboration with the Mayo clinic to develop Telo’s lead product, a prognostic test for SMM patients.
The company’s lead product targets high-risk SMM patients that will benefit from immediate treatment intervention.
It also can confirm disease stability of low-risk SMM patients who can be safely monitored by follow-up tests every three months.
The development stages and validation are expected to be completed within 12-18 months.
The test can benefit over 200,000 SMM patients in the USA, with the potential to issue over 500,000 tests per year.
Telo also has conducted several internal research and development projects to maximize accuracy and elevate its efficiency.
These projects included increased automation and batch processing to the microscopy component of the workflow
Also, an introduction of AI algorithms facilitates automated target cell selection has been worked on.
The completion of projects increases the efficiency and productivity of Telo by over 40 per cent.
Telo Genomics Corp. (TELO) is unchanged trading at $0.32 per share as of 11:16 a.m. EST.
